Featured Research

from universities, journals, and other organizations

Combination Treatment Enhances Tetanus Vaccination

Date:
September 15, 2005
Source:
Penn State
Summary:
In studies with mice, Penn State researchers have shown that a combination of retinoic acid -- a product the body makes naturally from vitamin A -- and PIC, a synthetic immunity booster, significantly elevates the immune system response to a tetanus shot.

In studies with mice, Penn State researchers have shown that acombination of retinoic acid -- a product the body makes naturally fromvitamin A -- and PIC, a synthetic immunity booster, significantlyelevates the immune system response to a tetanus shot.

Dr. A. Catharine Ross, who holds the Dorothy Foehr Huck Chair inNutrition at Penn State, directed the study. She says, "There aren'tvery many examples of using nutrition to improve immune response. Theseresults show that a natural product of vitamin A can have an importantrole in regulating immunity and, when administered along with PIC,might be a potentially powerful nutritional-immunological assist invaccination."

The researchers reported their findings today (Monday, Sept.12) in the online early edition of the Proceedings of the NationalAcademy of Sciences. The paper is "The anti-tetanus immune response ofneonatal mice is augmented by retinoic acid combined withpolyriboinosinic:polyribocytidylic acid." The first author is Yifan Ma,doctoral candidate in the Graduate Program in Integrative Biosciences,the Department of Nutritional Sciences and the Huck Institute for LifeSciences.

In previous studies, the Penn State researchers had shown thatretinoic acid boosts the adult mouse response to the tetanus vaccine.In the current investigation, they studied the response in week-oldmice. Mouse pups, like human infants, have a weaker response tovaccination than do adults due to the immaturity of their immunesystem.

Ross notes, "Strategies to enhance vaccination efficiency in early life are highly sought."

In the most recent Penn State experiments, week-old mice weregiven oral doses of retinoic acid along with a tetanus shot. The pupsthat received the retinoic acid developed a four times better immuneresponse than mice that didn't receive the vitamin A product. Mice thatreceived both retinoic acid and, PIC, the synthetic immunity boosterpolyriboinosinic: polyribocytidylic acid, developed a seven timeshigher immune response.

In addition, the researchers found that the combined retinoicacid/PIC treatment produced a more balanced enhancement than eitherretinoic acid or PIC alone.

Ross explains that the researchers measured three subtypes oftetanus antibodies in blood samples from the mouse pups aftervaccination. Both retinoic acid and PIC, when administered alone, eachincreased the antibodies about four-fold over all but the combinationretinoic acid/PIC treatment resulted in elevated levels that hadproportions of antibody types most like untreated pups.

Vitamin A is already given to children who are deficient inthis vitamin when they receive the measles ordiptheria-pertussis-tetanus vaccination and the intervention has beenshown to significantly elevate the vaccine-induced antibody responses.However, dosing non-deficient children with vitamin A cannot beexpected to have the same results as retinoic acid.

Ross explains that the human body makes retinoic acid fromingested vitamin A in very controlled amounts. Eating higher amounts ofvitamin A doesn't automatically result in higher levels of retinoicacid in the body.

###

The research was supportedby a grant from the National Institute of Health, the Penn State HuckInstitute for the Life Sciences and the Dorothy Foehr Huck Chair inNutrition.


Story Source:

The above story is based on materials provided by Penn State. Note: Materials may be edited for content and length.


Cite This Page:

Penn State. "Combination Treatment Enhances Tetanus Vaccination." ScienceDaily. ScienceDaily, 15 September 2005. <www.sciencedaily.com/releases/2005/09/050915002122.htm>.
Penn State. (2005, September 15). Combination Treatment Enhances Tetanus Vaccination. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/09/050915002122.htm
Penn State. "Combination Treatment Enhances Tetanus Vaccination." ScienceDaily. www.sciencedaily.com/releases/2005/09/050915002122.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins